The three new patents add to the company's existing portfolio and extend protection of the company's proprietary transdermal technology through at least 2028. Agile has also received a notice of allowance from the USPTO for the trademark Twirla(TM), and conditional acceptance from the FDA to use the proprietary name "Twirla" for its AG200-15 contraceptive patch, pending final agency review prior to NDA approval.
"We are thrilled that the USPTO issued these additional patents -- it underscores the proprietary nature of our transdermal technology and enhances the value of our intellectual property estate," said Al Altomari, President and CEO of Agile Therapeutics. "We are continuing to develop our patent portfolio in key markets around the world and the expansion in the U.S. is a great step forward."
Agile Therapeutics announces three new U.S. patents on its technology and the brand name Twirla(TM) for its first contraceptive patch
Agile Therapeutics today announced that the U.S. Patent and Trademark Office (USPTO) has issued three new patents with claims related to its contraceptive patch technology.
Aug 31, 2012
Companies in this article
LAST CHANCE TO SAVE! New Tech for Life Sciences at PACK EXPO Southeast
The exciting new PACK EXPO Southeast 2025 unites all vertical markets in one dynamic hub, generating more innovative answers to packaging challenges for life sciences products. Don’t miss this extraordinary opportunity for your business!
REGISTER ASAP FOR $30!